In this article, I revisit the question of whether HIV can ever be reimagined and re-embodied as a potentially non-infectious condition, drawing on a current qualitative study of couples with mixed HIV status (serodiscordance) in Australia. Recent clinical trials have consolidated a shift in scientific understandings of HIV infectiousness by showing that antiretroviral treatment effectively prevents the sexual transmission of HIV. Contrary to common critiques, I explore how the increasing biomedicalisation of public health and the allied discourse of 'normalisation' can in fact de-marginalise stigmatised relationships and sexualities. Invoking Ecks's concept of 'pharmaceutical citizenship', I consider whether the emerging global strategy of HIV 'treatment-as-prevention' (TasP) can open up new trajectories that release serodiscordant sexuality from its historical moorings in discourses of risk and stigma, and whether these processes might re-inscribe serodiscordant sexuality as 'normal' and safe, potentially shifting the emphasis in HIV prevention discourses away from sexual practice toward treatment uptake and adherence.

Download full-text PDF

Source
http://dx.doi.org/10.1111/1467-9566.12347DOI Listing

Publication Analysis

Top Keywords

serodiscordant sexuality
12
couples mixed
8
mixed hiv
8
hiv status
8
hiv
7
'the changed'
4
changed' pharmaceutical
4
pharmaceutical citizenship
4
citizenship reimagining
4
reimagining serodiscordant
4

Similar Publications

Oral pre-exposure prophylaxis implementation in South Africa: a case study of USAID-supported programs.

Front Reprod Health

December 2024

Bilateral Health Office, United States Agency for International Development, Pretoria, South Africa.

Since the introduction of oral pre-exposure prophylaxis (PrEP) in 2016, countries have successfully scaled-up PrEP to populations at risk of HIV acquisition, including key populations, serodiscordant couples and pregnant women. Between 2016 and 2023, there were over 5.6 million oral PrEP initiations globally.

View Article and Find Full Text PDF

In China, pre-exposure prophylaxis (PrEP) uptake among men who have sex with men (MSM) and HIV-serodiscordant couples is low. We offered differentiated PrEP options tailored to MSM in a community-based organization (CBO) setting, and to HIV-serodiscordant couples attempting conception in a specialized HIV care clinic. The CBO facilitated PrEP by linkage with a telemedicine platform for virtual consultation; additional online follow-up on social media was conducted by peers.

View Article and Find Full Text PDF

Background: HIV is a globally prevalent infection for which there is currently no cure or vaccine. As the number of individuals with HIV infection increases, so does the number of individuals wishing to have children despite being infected. This situation has highlighted issues related to couples where one partner is infected while the other is not (serodiscordant couples) and couples where both partners are positive.

View Article and Find Full Text PDF

Background: Non-disclosure of HIV status and poor condom use, among mothers living with HIV may pose risks of HIV transmission to their serodiscordant partners and may influence the outcome of their infants. The study was aimed at assessing predictors of HIV status disclosure, and condom use, among mothers of infants exposed to HIV attending the ART clinic in Abakaliki, Southeast Nigeria.

Materials And Methods: A hospital-based cross-sectional study that involved 246 mothers living with HIV.

View Article and Find Full Text PDF

Genital Herpes: Rapid Evidence Review.

Am Fam Physician

November 2024

Eglin Air Force Base Family Medicine Residency Program in Florida.

Article Synopsis
  • - Genital herpes, caused by herpes simplex virus (HSV) types 1 or 2, is a lifelong sexually transmitted infection affecting over 500 million people globally, with no available vaccines for prevention.
  • - It is characterized by painful genital lesions and flu-like symptoms; diagnosis is typically made through laboratory tests like PCR or viral culture.
  • - Treatment includes antiviral medications to manage outbreaks and reduce transmission, and pregnant individuals with a history of genital herpes are advised to start antiviral therapy at 36 weeks and may require a cesarean section if lesions are present.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!